Omeros (OMER) Earnings Date & Reports

Key Takeaways

• Omeros Corporation (OMER) is expected to report third-quarter 2026 results after the market close on November 11, 2026, for the quarter ending September 30, 2026.
• Wall Street consensus points to a roughly breakeven quarter, with recent estimates clustered around a loss of $0.05 per share, while revenue forecasts sit in the range of approximately $17 million to $19 million.
• The dominant story remains the commercial ramp of YARTEMLEA (narsoplimab), Omeros' newly launched treatment for transplant-associated thrombotic microangiopathy (TA-TMA), a rare and serious clotting complication following stem cell transplant.
• Investors will watch gross-to-net adjustments, cash burn, and management's progress toward its stated target of positive cash flow in 2027.
• Reimbursement catalysts, including a new CMS "J-code" effective July 1, 2026, and a New Technology Add-On Payment (NTAP) effective October 1, 2026, are expected to support revenue in the back half of the year.

Earnings Context and Why It Matters

Omeros has transformed from a clinical-stage biopharmaceutical company into a commercial-stage one following the U.S. Food and Drug Administration (FDA) approval of YARTEMLEA and its January 2026 launch. The third-quarter report is the second full quarter of scaled commercial sales and will test whether the rapid launch momentum seen earlier in the year can be sustained. In the second quarter of 2026, YARTEMLEA gross revenue jumped 190% sequentially to $32.2 million, driving net revenue of $28.5 million and a surprise profit. For investors, this print is a critical read on reimbursement progress, market penetration across transplant centers, and the path toward sustainable profitability.

Earnings Expectations

Analyst estimates have shifted meaningfully following the stronger-than-expected second quarter. Consensus forecasts now call for a narrow loss of approximately $0.05 per share, though some data providers show the figure approaching breakeven, reflecting upward revisions after the August results. Revenue consensus sits around $17 million to $19 million, implying a sequential step-down from the $28.5 million reported in the second quarter — a point worth watching, since prior quarters showed rapid growth rather than contraction.

Beyond the headline numbers, the metrics that matter are YARTEMLEA net and gross sales, the gross-to-net adjustment (which ran near 11.5% in the second quarter), and operating expenses. Omeros' results are also complicated by non-cash mark-to-market adjustments tied to its convertible notes; on a non-GAAP (non-generally accepted accounting principles) basis, the company posted adjusted net income of $1.8 million, or $0.02 per share, in the second quarter. Historically, OMER shares have reacted sharply to these reports, surging roughly 26% after the second-quarter beat.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking biopharmaceutical names like Omeros, it can help identify peers, momentum shifts, and technical setups ahead of major catalysts. Explore the AI Screener to streamline your research workflow.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter print is broadly positive but cautious. OMER shares rallied strongly after the second-quarter earnings beat, and the stock has carried a positive post-earnings drift since August, trading near the higher end of its 52-week range. The bullish case centers on YARTEMLEA's launch execution and a pipeline bolstered by the Novo Nordisk partnership for zaltenibart. Key risks include the possibility of a sequential revenue dip, slower-than-expected reimbursement adoption, elevated spending on commercial infrastructure, and dilution from convertible debt or equity financings. Because Omeros results are heavily influenced by non-cash derivative adjustments, investors often look through GAAP figures to the underlying operating performance, which can create volatile one-day price swings around the release.

Forward Outlook and Key Factors to Monitor

Following the earnings report, investors should track several catalysts tied to YARTEMLEA's commercial trajectory. The permanent CMS J-code and the New Technology Add-On Payment, effective October 1, 2026, are designed to ease hospital billing and reimbursement, and management commentary on how these tools are translating into real-world demand will be closely scrutinized.

On the clinical front, Omeros has guided toward beginning enrollment in two new YARTEMLEA studies by year-end 2026 — one in hyperinflammatory acute respiratory distress syndrome (ARDS) and another in prophylactic use for high-risk pediatric TA-TMA patients. Progress on OMS527 for cocaine use disorder and the OncotoX-AML oncology program, where a first-in-human trial is targeted for late 2027, also matters for the longer-term narrative.

Finally, balance-sheet discipline will remain a focal point. With $132.0 million in cash and short-term investments at the end of June 2026 and a stated goal of positive cash flow in 2027, investors will watch operating cash generation, gross-to-net trends, and any updates to expense or financing plans.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations